Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.38 +7.6% TUNG 1.72 +1.8% LGO 1.01 −2.4% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.30 −2.0% SGZ 0.045 +0.0% S 0.135 +12.5% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.73 −0.9% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.38 +7.6% TUNG 1.72 +1.8% LGO 1.01 −2.4% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.30 −2.0% SGZ 0.045 +0.0% S 0.135 +12.5% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.73 −0.9%
Financings

Doseology shares begin trading on OTCQB Venture Market

By The Northwire Desk — AI Analysis Mar 11, 2026 · 16:48 MOOD · 0.72 Doseology Sciences Inc
MOOD · Price

Executive Summary

  • Doseology Sciences Inc. has commenced trading on the OTCQB Venture Market under the symbol DOSEF, expanding U.S. investor access and aligning with higher transparency standards.
  • The company issued 75,000 prefinanced warrants to the vendor of the "Feed That Brain" acquisition, with additional issuances scheduled for the one-year and 18-month anniversaries of the closing.
  • The release highlights the company's strategic positioning in the emerging oral stimulant pouch category, including the acquisition of the Feed That Brain brand and plans for proprietary stimulant technologies.

Key Details

  • Listing Update: Common shares commenced trading on the OTCQB Venture Market under the symbol DOSEF.
  • Warrant Issuance (Feed That Brain Acquisition):
    • Issued an aggregate of 75,000 prefinanced warrants to the vendor (Joseph Mimran & Associates Inc.).
    • Deemed price: $1 per prefinanced warrant.
    • Total value of initial issuance: $75,000.
    • Future issuances: Additional $75,000 worth of prefinanced warrants due on the one-year and 18-month anniversaries of the acquisition closing.
    • Hold Period: Four-month hold period expires on July 11, 2026.
  • Management Changes: Appointment of Larry Latowsky as executive chairman of the board of directors to support compliance with new market standards.
  • Acquisition Context: The warrant issuance follows the closing of the acquisition of the Feed That Brain division operated by Joseph Mimran & Associates Inc., announced on August 27, 2025.
  • Strategic Positioning: Doseology is positioning itself as a pure-play public company in the oral stimulant pouch category, combining product development with direct-to-consumer distribution.
  • Product Pipeline: Exploring proprietary stimulant technologies, including next-generation caffeine analogues and nicotine alternatives for modern oral delivery formats.
  • Brand Portfolio: Includes the recently acquired retail brand "Feed That Brain."

Notable Quotes

  • "We are pleased to expand trading access for U.S. investors through the OTCQB market... Trading on OTCQB aligns the company with higher standards of financial reporting and disclosure, providing greater transparency and confidence for investors as we execute our long-term growth strategy." — Chris Jackson, CEO
Read the original news release →

More from Doseology Sciences Inc

Jun 29, 2026 · 19:21

Doseology Announces Extension to Closing of Private Placement

Financings May 15, 2026 · 22:24

Doseology extends financing, president Corkum resigns

Financings Mar 11, 2026 · 07:00

Doseology Uplists to OTCQB as DOSEF, Expanding U.S. Investor Access to the Emerging Oral Stimulant Pouch Category

Financings Mar 04, 2026 · 13:13

Doseology Sciences rolls out Feed That Brain product

Other Mar 04, 2026 · 07:00

Doseology Launches Feed That Brain(TM) Oral Stimulant Pouches in the U.S. Through Direct-to-Consumer Pilot

Other Feb 27, 2026 · 16:05

SEDAR Interim Financial Statements

None